Trials / Completed
CompletedNCT04464395
Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients
Immunotherapy of COVID-19 With B-Cell Activating CPI-006 Monoclonal Antibody
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Corvus Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 1 single-dose, dose-escalation study is an open label trial evaluating the safety of CPI-006, a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase, as immunotherapy for stable hospitalized mild or moderately symptomatic COVID-19 patients with a parallel non-randomized Control Arm for treatment with standard of care only.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CPI-006 | Participants will receive a single dose of CPI-006 at one of four dose levels (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 5.0 mg/kg) along with standard of care. |
| OTHER | Standard of Care | Participants will receive standard of care treatment only. |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2021-03-01
- Completion
- 2021-07-09
- First posted
- 2020-07-09
- Last updated
- 2021-07-21
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04464395. Inclusion in this directory is not an endorsement.